Discover undervalued stocks with Eulerpool.

Subscribe for $2

Pulmonx Stock LUNG

Price

0
Today +/-
-0
Today %
-0 %

Pulmonx stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pulmonx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pulmonx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pulmonx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pulmonx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pulmonx Stock Price History

DatePulmonx Price
10/9/20250 undefined
10/9/20251.74 undefined
10/8/20251.79 undefined
10/7/20251.72 undefined
10/6/20251.75 undefined
10/3/20251.84 undefined
10/2/20251.70 undefined
10/1/20251.67 undefined
9/30/20251.60 undefined
9/28/20251.65 undefined
9/25/20251.74 undefined
9/24/20251.71 undefined
9/24/20251.79 undefined
9/23/20251.82 undefined
9/22/20251.87 undefined
9/19/20251.75 undefined
9/19/20251.71 undefined
9/18/20251.61 undefined
9/17/20251.58 undefined
9/16/20251.60 undefined
9/15/20251.61 undefined
9/12/20251.69 undefined
9/12/20251.69 undefined
9/11/20251.68 undefined
9/10/20251.63 undefined
9/9/20251.70 undefined

Pulmonx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pulmonx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pulmonx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pulmonx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pulmonx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pulmonx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pulmonx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pulmonx’s growth potential.

Pulmonx Revenue, EBIT and net profit per share

DatePulmonx RevenuePulmonx EBITPulmonx Net Income
2030e438.08 M undefined0 undefined148.39 M undefined
2029e327.65 M undefined102.29 M undefined87.08 M undefined
2028e182.33 M undefined309,396.6 undefined-1.25 M undefined
2027e129.37 M undefined-38.37 M undefined-35.5 M undefined
2026e106.03 M undefined-56.86 M undefined-55.35 M undefined
2025e92.42 M undefined-63.63 M undefined-64.29 M undefined
202483.79 M undefined-56 M undefined-56.39 M undefined
202368.68 M undefined-61.94 M undefined-60.84 M undefined
202253.66 M undefined-58.64 M undefined-58.92 M undefined
202148.42 M undefined-47.3 M undefined-48.66 M undefined
202032.73 M undefined-32.33 M undefined-32.23 M undefined
201932.6 M undefined-17.84 M undefined-20.7 M undefined
201820 M undefined-15.05 M undefined-18.48 M undefined

Pulmonx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20182019202020212022202320242025e2026e2027e2028e2029e2030e
2032324853688392106129182327438
-60.00-50.0010.4228.3022.0610.8415.2221.7041.0979.6733.94
60.0068.7565.6372.9273.5873.5374.7067.3958.4948.0634.0718.9614.16
12222135395062000000
-18-20-32-48-58-60-56-64-55-35-187148
-11.1160.0050.0020.833.45-6.6714.29-14.06-36.36-97.14-8,800.0070.11
33.9333.9335.6936.1337.137.9739.11000000
- - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Pulmonx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pulmonx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (k)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (k)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2018201920202021202220232024
             
4.128.3231.6180141.1117.1101.48
35.54.26.68.712.1113.12
400400400300600915671
3.35.610.716.314.616.7416.92
0.41.23.14.843.564.06
11.241250208169150.42136.25
0.47.510.512.910.57.4321.45
00010.95.914.390
0000000
600500400300200310
2.32.32.32.32.32.332.33
0.42.10.50.75.83.172.82
3.712.413.727.124.727.3626.6
14.953.4263.7235.1193.7177.78162.85
             
140.5205.30000.040.04
21.121.7467.1482.9502.7526.8551.21
-189.8-210.5-242.7-291.4-350.3-411.16-467.56
1.31.41.71.71.62.642.11
0000000
-26.917.9226.1193.2154118.3285.81
1.32.71.51.61.81.53.83
5.59.19.614.31618.8516.24
1.32.41.41.50.70.661.2
0000000
0000.10.12.163.18
8.114.212.517.518.623.1624.44
33.61517.417.317.235.0934
00100010011487
0.16.47.673.81.1118.52
33.721.425.124.321.136.3152.6
41.835.637.641.839.759.4777.04
14.953.5263.7235193.7177.78162.85
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pulmonx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pulmonx's financial health and stability.

Assets

Pulmonx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pulmonx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pulmonx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pulmonx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201820192020202120222023
-18-20-32-48-58-60
00001,0001,000
000000
-1-2-4-7-7-2
129243546
113002
000000
-18-20-30-41-45-37
000-3-10
0-1412-46-4-2
0-1313-42-2-1
000000
126320019
040206421
12452344221
---4.00---
000000
-510217-83-46-18
-18.71-21.49-31.54-45.06-46.4-38.42
000000

Pulmonx stock margins

The Pulmonx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pulmonx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pulmonx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pulmonx's sales revenue. A higher gross margin percentage indicates that the Pulmonx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pulmonx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pulmonx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pulmonx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pulmonx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pulmonx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pulmonx Margin History

Pulmonx Gross marginPulmonx Profit marginPulmonx EBIT marginPulmonx Profit margin
2030e74 %0 %33.87 %
2029e74 %31.22 %26.58 %
2028e74 %0.17 %-0.68 %
2027e74 %-29.66 %-27.44 %
2026e74 %-53.62 %-52.2 %
2025e74 %-68.84 %-69.56 %
202474 %-66.84 %-67.3 %
202373.9 %-90.19 %-88.6 %
202274.3 %-109.28 %-109.8 %
202173.59 %-97.69 %-100.5 %
202064.77 %-98.78 %-98.47 %
201968.74 %-54.72 %-63.5 %
201861.45 %-75.25 %-92.4 %

Pulmonx Stock Sales Revenue, EBIT, Earnings per Share

The Pulmonx earnings per share therefore indicates how much revenue Pulmonx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pulmonx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pulmonx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pulmonx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pulmonx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pulmonx Revenue, EBIT and net profit per share

DatePulmonx Sales per SharePulmonx EBIT per sharePulmonx Earnings per Share
2030e10.75 undefined0 undefined3.64 undefined
2029e8.04 undefined0 undefined2.14 undefined
2028e4.47 undefined0 undefined-0.03 undefined
2027e3.17 undefined0 undefined-0.87 undefined
2026e2.6 undefined0 undefined-1.36 undefined
2025e2.27 undefined0 undefined-1.58 undefined
20242.14 undefined-1.43 undefined-1.44 undefined
20231.81 undefined-1.63 undefined-1.6 undefined
20221.45 undefined-1.58 undefined-1.59 undefined
20211.34 undefined-1.31 undefined-1.35 undefined
20200.92 undefined-0.91 undefined-0.9 undefined
20190.96 undefined-0.53 undefined-0.61 undefined
20180.59 undefined-0.44 undefined-0.54 undefined

Pulmonx business model

Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.com.

Pulmonx SWOT Analysis

Strengths

Pulmonx Corp has several notable strengths:

  • Leading technology in the field of minimally invasive interventional pulmonology.
  • Strong intellectual property portfolio, providing a competitive advantage.
  • Established partnerships with key healthcare organizations and professionals.
  • Proven track record of successful product development and commercialization.
  • Robust financial position to support ongoing innovation and growth.

Weaknesses

Pulmonx Corp faces the following weaknesses:

  • Relatively limited product portfolio compared to some competitors.
  • Dependence on regulatory approvals for product launches and market expansion.
  • Need for continued investment in research and development to stay ahead of emerging technologies.
  • Limited global presence, with a focus primarily on certain markets.

Opportunities

Pulmonx Corp can explore the following opportunities:

  • Increasing demand for minimally invasive procedures in the healthcare industry.
  • Expanding into untapped geographic markets to reach a wider customer base.
  • Collaborating with healthcare providers to develop and promote new treatment options.
  • Acquiring or partnering with complementary businesses to enhance product offerings.
  • Capitalizing on the growing trend of personalized medicine to deliver targeted solutions.

Threats

Pulmonx Corp should be aware of the following threats:

  • Intense competition from established players and new entrants in the industry.
  • Potential regulatory challenges and changes that may impact product development and commercialization.
  • Economic downturns or market fluctuations that could affect customer spending.
  • Rapid technological advancements that may render existing products outdated.
  • Reimbursement uncertainties and pricing pressures in healthcare systems.

Pulmonx Revenue by Region

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Pulmonx Revenue by Segment

DateAsia PacificEurope, Middle-East and AfricaEurope, Middle-East and Africa (“EMEA”)Other InternationalUnited States
20233.02 M USD-19.34 M USD399,000 USD45.92 M USD
20222.87 M USD-18.15 M USD155,000 USD32.49 M USD
20213.41 M USD-19.88 M USD128,000 USD24.99 M USD
20202.69 M USD13.81 M USD-49,000 USD16.19 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Pulmonx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pulmonx historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Pulmonx shares outstanding

The number of shares was Pulmonx in 2024 — This indicates how many shares 39.111 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pulmonx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pulmonx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pulmonx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pulmonx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Pulmonx.

Pulmonx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.38 -0.38  (0.21 %)2025 Q2
3/31/2025-0.38 -0.36  (5.31 %)2025 Q1
12/31/2024-0.46 -0.33  (27.71 %)2024 Q4
9/30/2024-0.46 -0.36  (21.31 %)2024 Q3
6/30/2024-0.43 -0.35  (19.3 %)2024 Q2
3/31/2024-0.47 -0.36  (23.5 %)2024 Q1
12/31/2023-0.42 -0.36  (13.32 %)2023 Q4
9/30/2023-0.44 -0.39  (10.63 %)2023 Q3
6/30/2023-0.45 -0.43  (3.5 %)2023 Q2
3/31/2023-0.45 -0.42  (6.42 %)2023 Q1
1
2

Eulerpool ESG Scorecard© for the Pulmonx stock

Eulerpool World ESG Rating (EESG©)

23/ 100

🌱 Environment

4

👫 Social

37

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pulmonx shareholders

%
Name
Stocks
Change
Date
12.67406 % PRIMECAP Management Company5,164,681-250,0806/30/2025
10.38107 % Fidelity Management & Research Company LLC4,230,286-483,0256/30/2025
7.20357 % Morgan Stanley & Co. LLC2,935,4537,8546/30/2025
6.01072 % BlackRock Institutional Trust Company, N.A.2,449,368-88,3276/30/2025
5.62942 % The Vanguard Group, Inc.2,293,98811,6816/30/2025
4.63804 % Deerfield Management Company, L.P.1,890,00006/30/2025
2.86752 % BNP Paribas Asset Management USA, Inc.1,168,513-83,3516/30/2025
2.86264 % Millennium Management LLC1,166,527958,0486/30/2025
2.76085 % DWS Investments UK Limited1,125,045-6,1866/30/2025
2.28358 % Silvercrest Asset Management Group LLC930,55706/30/2025
1
2
3
4
5
...
10

Pulmonx Executives and Management Board

Mr. Steven Williamson

(52)
Pulmonx President, Chief Executive Officer, Director (since 2024)
Compensation 5.23 M

Mr. Mehul Joshi

(64)
Pulmonx Chief Financial Officer
Compensation 3.24 M

Mr. Geoffrey Rose

(51)
Pulmonx Chief Commercial Officer
Compensation 1.96 M

Mr. David Lehman

(64)
Pulmonx General Counsel
Compensation 1.49 M

Mr. Glendon French

(63)
Pulmonx Director (since 2014)
Compensation 330,786
1
2
3

Most common questions regarding Pulmonx

What values and corporate philosophy does Pulmonx represent?

Pulmonx Corp represents a strong commitment to improving the lives of patients with severe lung diseases. Their corporate philosophy revolves around innovation, patient-centricity, and clinical excellence. The company values inclusivity, collaboration, and integrity in their pursuit of developing novel therapeutic solutions. Pulmonx Corp focuses on providing minimally invasive devices and technologies that offer better treatment options for conditions like chronic obstructive pulmonary disease (COPD) and emphysema. With a mission to enhance lung health, Pulmonx Corp continuously strives to advance medical knowledge, improve patient outcomes, and contribute to global respiratory innovation.

In which countries and regions is Pulmonx primarily present?

Pulmonx Corp is primarily present in various countries and regions around the world. These include the United States, Europe, Asia-Pacific, and Latin America.

What significant milestones has the company Pulmonx achieved?

Pulmonx Corp has achieved significant milestones in its journey. The company developed an innovative solution known as Zephyr Valve, which has revolutionized the treatment of severe emphysema. Pulmonx Corp received FDA approval for Zephyr Valve, making it the first minimally invasive implant to offer lung volume reduction in emphysema patients. This milestone marked a major breakthrough in the field of respiratory care. Additionally, Pulmonx Corp has expanded its global reach and established partnerships with renowned medical centers worldwide. These achievements highlight the company's commitment to improving the lives of patients suffering from debilitating lung diseases.

What is the history and background of the company Pulmonx?

Pulmonx Corp is a leading medical technology company specializing in minimally invasive devices for patients suffering from severe lung diseases. Established in 1997, Pulmonx has dedicated its efforts to improving the lives of those with chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's innovative products, such as the Zephyr Valve System, offer a novel approach to lung disease treatment, providing patients with a non-surgical option that reduces hyperinflation and improves lung function. Pulmonx Corp has emerged as a global leader in the field, helping patients worldwide breathe easier and enhancing their quality of life.

Who are the main competitors of Pulmonx in the market?

The main competitors of Pulmonx Corp in the market are Boston Scientific Corporation and Olympus Corporation.

In which industries is Pulmonx primarily active?

Pulmonx Corp is primarily active in the medical device industry.

What is the business model of Pulmonx?

The business model of Pulmonx Corp focuses on developing and commercializing minimally invasive medical devices for the treatment of severe respiratory diseases. The company specializes in creating novel solutions for conditions like emphysema and chronic bronchitis, offering patients and healthcare providers effective alternatives to traditional treatments. Pulmonx Corp's innovative technologies, such as the Zephyr Valve System, help improve lung function and quality of life for individuals suffering from severe respiratory conditions. With a strong emphasis on research, development, and collaboration, Pulmonx Corp strives to bring about advancements in respiratory care and provide targeted therapies for patients worldwide.

What is the P/E ratio of Pulmonx 2025?

The P/E ratio cannot be calculated for Pulmonx at the moment.

What is the P/S ratio of Pulmonx 2025?

The P/S cannot be calculated for Pulmonx currently.

What is the Quality Investing of Pulmonx?

The Quality Investing for Pulmonx is 4/10.

What is the revenue of Pulmonx 2025?

The expected Pulmonx revenue is 92.42 M USD.

How high is the profit of Pulmonx 2025?

The expected Pulmonx profit is -64.29 M USD.

What is the business model of Pulmonx

The company Pulmonx Corp is a leading manufacturer of medical devices that help patients with respiratory diseases. The company is headquartered in Redwood City, California and has branches all over the world. Pulmonx Corp's business model is based on the development, manufacturing, and marketing of products for the treatment of lung and respiratory diseases. There are several business areas that the company serves: 1. Endobronchial therapy Pulmonx Corp has developed a unique procedure for endobronchial therapy, in which a small implant is inserted into the trachea to open the airways. The procedure is particularly effective in patients with severe emphysema or chronic obstructive pulmonary disease (COPD). 2. Diagnostics The company also offers a wide range of diagnostic tests for respiratory diseases. These tests help doctors make the correct diagnosis and plan the best treatment for the patient. 3. Training and education Pulmonx Corp also operates an extensive training and education program for doctors and medical staff. The company offers a variety of workshops and training sessions for endobronchial therapy to ensure that doctors can use the technology safely and effectively. 4. Research and development An important part of Pulmonx's business model is the continuous research and development of new products and technologies for the treatment of respiratory diseases. The company invests significant resources in developing new implants for endobronchial therapy and researching new diagnostic tests. One example of a product offered by Pulmonx Corp is the Zephyr Valve. This is a small, implantable device that is placed in the patient's bronchi. The valve allows the patient to breathe more effectively by improving lung ventilation and expanding the airways. The valve is implanted using an endobronchial catheter and can usually be done on an outpatient basis. Most patients can go home the next day. Overall, Pulmonx Corp's business model has proven to be extremely successful. The company has carved out a unique niche in the respiratory technology market and is on its way to becoming a leading provider of endobronchial therapies and diagnostic tests. The company relies on scientifically based innovations to improve the health of people with respiratory diseases.

What is the Pulmonx dividend?

Pulmonx pays a dividend of 0 USD distributed over payouts per year.

How often does Pulmonx pay dividends?

The dividend cannot currently be calculated for Pulmonx or the company does not pay out a dividend.

What is the Pulmonx ISIN?

The ISIN of Pulmonx is US7458481014.

What is the Pulmonx WKN?

The WKN of Pulmonx is A2P1AF.

What is the Pulmonx ticker?

The ticker of Pulmonx is LUNG.

How much dividend does Pulmonx pay?

Over the past 12 months, Pulmonx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pulmonx is expected to pay a dividend of 0 USD.

What is the dividend yield of Pulmonx?

The current dividend yield of Pulmonx is .

When does Pulmonx pay dividends?

Pulmonx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pulmonx?

Pulmonx paid dividends every year for the past 0 years.

What is the dividend of Pulmonx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pulmonx located?

Pulmonx is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pulmonx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pulmonx from 10/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2025.

When did Pulmonx pay the last dividend?

The last dividend was paid out on 10/10/2025.

What was the dividend of Pulmonx in the year 2024?

In the year 2024, Pulmonx distributed 0 USD as dividends.

In which currency does Pulmonx pay out the dividend?

The dividends of Pulmonx are distributed in USD.

All fundamentals about Pulmonx

Our stock analysis for Pulmonx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pulmonx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.